Impact ofABCB1Allelic Variants on QTc Interval Prolongation
Open Access
- 15 February 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (4), 937-946
- https://doi.org/10.1158/1078-0432.ccr-10-0925
Abstract
Purpose: Although the ABCB1 (P-glycoprotein) drug transporter is a constituent of several blood–tissue barriers (i.e., blood–brain and blood–nerve), its participation in a putative blood–heart barrier has been poorly explored. ABCB1 could decrease the intracardiac concentrations of drugs that cause QT prolongation and cardiotoxicity.Experimental Design: ABCB1-related romidepsin transport kinetics were explored in LLC-PK1 cells transfected with different ABCB1 genetic variants. ABCB1 plasma and intracardiac concentrations were determined in Abcb1a/1b (−/−) mice and wild-type FVB controls. These same mice were used to evaluate romidepsin-induced heart rate-corrected QT interval (QTc) prolongation over time. Finally, a cohort of 83 individuals with available QTcB and ABCB1 genotyping data were used to compare allelic variation in ABCB1 versus QTc-prolongation phenotype.Results: Here, we show that mice lacking the ABCB1-type P-glycoprotein have higher intracardiac concentrations of a model ABCB1 substrate, romidepsin, that correspond to changes in QT prolongation from baseline (ΔQTc) over time. Consistent with this observation, we also show that patients carrying genetic variants that could raise ABCB1 expression in the cardiac endothelium have lower ΔQTc following a single dose of romidepsin.Conclusions: To our knowledge, this is the first evidence that Abcb1-type P-glycoprotein can limit intracardiac exposure to a drug that mediates QT prolongation and suggests that certain commonly inherited polymorphisms in ABCB1 may serve as markers for QT prolongation following the administration of ABCB1-substrate drugs. Clin Cancer Res; 17(4); 937–46. ©2010 AACR.Other Versions
This publication has 49 references indexed in Scilit:
- Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell LymphomaClinical Cancer Research, 2009
- ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with DocetaxelClinical Cancer Research, 2008
- Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detectionJournal of Chromatography B, 2008
- Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndromeBritish Journal of Pharmacology, 2008
- hERG channel trafficking: novel targets in drug-induced long QT syndromeBiochemical Society Transactions, 2007
- Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropeniaEuropean Journal of Cancer, 2006
- Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell LymphomaClinical Cancer Research, 2006
- T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistanceBlood, 2004
- Nicotine Induces a Long QT Phenotype in Kcnq1-Deficient Mouse HeartsThe Journal of pharmacology and experimental therapeutics, 2003
- Testing for the equality of area under the curves when using destructive measurement techniquesJournal of Pharmacokinetics and Biopharmaceutics, 1988